scholarly journals Effect of dose and time of vaccination on immune response of duck plague vaccine in ducks

1970 ◽  
Vol 2 (2) ◽  
pp. 117-119 ◽  
Author(s):  
MT Hossain ◽  
MA Islam ◽  
S Akter ◽  
M Sadekuzzaman ◽  
MA Islam ◽  
...  
Keyword(s):  
Immune Response ◽  
Field Isolate ◽  
Booster Vaccination ◽  
Primary Vaccination ◽  
Challenge Infection ◽  
Control Group ◽  
Duck Plague Virus ◽  
Unvaccinated Control ◽  
Plague Vaccine ◽  
Group D

Effect of dose and time of vaccination on immune response of duck plague vaccine in 90 (45 of 18-day-old and 45 of 35-day-old) Jinding ducklings was studied during the period from October 2002 to March 2003. Each of both age group (18-day-old and 35-day-old) was divided into three groups as A, B, C and D, E, F respectively, consisting of 15 ducklings in each. Each duckling of groups A and B was primarily vaccinated with 0.25 ml and 0.5 ml of duck plague vaccine (LRI, Mohakhali) intramuscularly at 18 days old respectively and could not be boosted due to the death of all the ducklings of both groups within 20 days of primary vaccination. Each duckling of group D and E received 0.5 ml and 1.0 ml of duck plague vaccine (LRI, Mohakhali) intramuscularly at 35 days old respectively and ducks of both the groups boosted with 1.0 ml of vaccine 5 months after primary vaccination. Groups C and F served as unvaccinated control. 14 days after booster vaccination ducks of group D, E and F were challenged with the virulent field isolate of duck plague virus @ 1.0 ml / duck IM (104 EID50 / dose). The ducklings of group D that were vaccinated primarily at 35 days old with 0.5 ml and boosted after 5 months with 1.0 ml of duck plague vaccine had significantly (p< 0.01) higher PHA titres after 2 weeks of primary vaccination (38.4 ± 6.4), booster vaccination (153.6 ± 25.6) and challenge infection (281.6 ± 62.71) in comparison to control group (≤4, ≤4 and 20.0 ± 2.3 respectively) and all the ducks survived (100%) after challenge. The ducklings of group E that were vaccinated primarily at 35 days old and boosted after 5 months of primary vaccination with 1.0 ml of duck plague vaccine had also significantly (p< 0.01) higher PHA titres after two weeks of booster vaccination (76.8 ± 12.8) and challenge infection (153.6 ± 25.6) in comparison to control group, but only 8 (53.3%) ducks could protect the challenge infection with virulent duck plague virus. It may be concluded that ducklings below 30 days of age should not be vaccinated with duck plague vaccine. It also may be proposed that primary vaccination at 35 days old with duck plague vaccine (LRI, Mohakhali) @ 0.5 ml / duckling and booster vaccination after 5 months of primary vaccination @ 1.0 ml could be practiced for better immune response against duck plague.Key words: effect; dose; age; immune response; duck plague vaccine; ducksdoi: 10.3329/bjvm.v2i2.2542Bangl. J. Vet. Med. (2004). 2 (2): 117-119

scholarly journals The Efficacy of Ranikhet Disease Vaccines Produced by Livestock Research Institute of Bangladesh

2013 ◽  
Vol 1 (1) ◽  
pp. 9-13 ◽  
Author(s):  
Sreebas Chandra Sarkar ◽  
Sukumar Saha ◽  
Md Mansurul Amin ◽  
Md Golzar Hossain
Keyword(s):  
Field Isolate ◽  
Challenge Infection ◽  
Control Group ◽  
Passive Protection ◽  
Field Virus ◽  
Unvaccinated Control ◽  
Antibody Titers ◽  
Group A ◽  
Group B ◽  
Research Institute

The study was conducted to investigate the efficacy of Baby chick Ranikhet Disease Vaccine (BCRDV) and Ranikhet Disease Vaccine (RDV) produced by the Livestock Research Institute (LRI), Mohakhali, Dhaka. For this experiment, 100 day-old-chick was purchased from Phinex Hatchery Ltd., Gazipur. The chicks (n=100) were divided into two groups. In group A (n=50), vaccination was performed twice with BCRDV at 2 and 21 days of age through intraocular route (i/o) followed by once with RDV at 60-day of age through intramuscular (i/m) route. Group B (n=50) was kept as unvaccinated control. The immunogenicity of the vaccine was evaluated by measuring the serum HI antibody titers at 1-, 20-, 36-, and 76-day of age, while the vaccine efficacy was examined by a challenge infection experiment with a velogenic field isolate of NDV as well as passive protection test. It was observed that the maternal antibody titers of the unvaccinated control group B gradually declined from day 1 to day 76 of age. Conversely, after primary and secondary vaccination with BCRDV, the levels of serum HI titer slightly increased in vaccinated group A compared with those in control group B. Finally administration of RDV resulted in a sharp increase in HI titer, leading to protection from challenge infection with virulent field virus as well as passive protection test. These results clearly demonstrated that a prime-booster immunization with BCRDV and RDV, both produced by LRI, is effective to protect chicken against Newcastle disease (ND).DOI: http://dx.doi.org/10.3329/mh.v1i1.13706 Microbes and Health Vol.1(1) June 2012 pp.9-13

scholarly journals IMMUNOGENIC RESPONSE WITH EFFICACY OF CERTAIN GUMBORO VACCINES IN BROILER

2012 ◽  
Vol 3 (1) ◽  
pp. 07-12
Author(s):  
MT Islam ◽  
MA Samad ◽  
MI Hossain
Keyword(s):  
Antibody Titre ◽  
Broiler Chickens ◽  
Booster Dose ◽  
Animal Health ◽  
Research Work ◽  
Booster Vaccination ◽  
Primary Vaccination ◽  
Challenge Infection ◽  
Unvaccinated Control ◽  
Immunogenic Response

The research work was carried out to determine the immunogenic response with efficacy of six commercial Gumboro, vaccines (Nobilis® Gumboro D78 and Nobilis® Gumboro 228E, Intervet, The Netherlands; Bur-706®, Merial, France; TAD Gumboro vac® and TAD Gumboro vac forte®, Lohmann Animal Health, Germany; BursaplexTM, Merial Select, Inc. Gainesville, USA) under experimental condition in broiler chickens during the period from November 2002 to May 2003. The chickens of two groups were vaccinated with Nobilis® Gumboro D78 and Nobilis® Gumboro 228E at 14 days of age with a booster dose at 21 days of age and were challenged at 40 days of age with vvIBDV. TAD Gumboro vac® and TAD Gumboro vac forte® were inoculated into the two groups of chickens at 14 and 28 days of age and the chickens were challenged at 35 days of age with vvIBDV. Bur-706® vaccine was given to the chickens of another group at one-day-old and 14 days of age and the chickens were challenged at 28 days of age. One group of chickens was vaccinated with Bursaplex™ vaccine at 1-day-old with no booster dose and was challenged at 21 days of age. The percentage of protection in birds receiving Nobilis® Gumboro D78 and Nobilis® Gumboro 228E vaccines by intraocular route was 92.30 and 96.29 respectively, whereas the percentages of protection in birds receiving TAD Gumboro vac®, TAD Gumboro, vac forte® and Bur-706® vaccines were 95.65, 100 and 95.83 respectively. BursaplxTM provided 100% protection against challenge with vvIBDV. Chickens vaccinated with Nobilis® Gumboro D78, Nobilis® Gumboro 228E, TAD Gumboro vac®, and Bur-706®, showed significant (p < 0.05, p < 0.01) decrease in ELISA antibody titre up to the day of challenge infection. BursaplexTM vaccinated group also showed significant decrease in ELISA antibody titre by 7 days (p < 0.05) and by 14 and 21 days (p < 0.01) after primary vaccination. In case of TAD Gumboro vac forte®, 7 days (839 ± 219.34) and 14 days (258 ± 44.80) after primary vaccination, the ELISA antibody titre significantly (p < 0.01) decreased but 7 days after booster vaccination, the ELISA antibody titre significantly (p < 0.01) increased (1299 ± 37.51). All the control sera revealed significant (p < 0.01) decrease of ELISA antibody titre up to day of challenge infection. There was an insignificant increase in ELISA antibody titre 7 days after booster vaccination in case of unvaccinated control groups for TAD Gumboro vac® and TAD Gumboro vac forte® only. Nobilis® Gumboro D78, TAD Gumboro vac® and Bur-706® vaccinated groups revealed significant (p < 0.01) increase of ELISA antibody titre 7 days post-challenge while Nobilis® Gumboro 228E and BursaplexTM vaccinated groups showed significant (p < 0.05) increase of antibody titre after 7 days of challenge. Insignificant increase of antibody titre was recorded in TAD Gumboro vac forte® vaccinated group. It may be concluded that TAD Gumboro vac forte® (intermediate plus) and BursaplexTM (Merial Select, Inc. Gainesville, USA) can be used to immunize the broiler birds sufficiently against IBD. However, it is necessary to estimate the optimum vaccination timing, i.e., to determine when maternal antibodies in chicks will decline to levels that the vaccines can overcome.

scholarly journals Comparative immunogenicity of fowl cholera vaccine in Jinding ducks

2014 ◽  
Vol 30 (2) ◽  
pp. 41-45 ◽  
Author(s):  
S Sultana ◽  
S Saha ◽  
MM Amin
Keyword(s):  
Pasteurella Multocida ◽  
Booster Vaccination ◽  
Primary Vaccination ◽  
Challenge Infection ◽  
Fowl Cholera ◽  
Significant Difference ◽  
Unvaccinated Control ◽  
Antibody Titres ◽  
Group A ◽  
Group B

This study compared the immunogenicity of alum-precipitated formalin-killed fowl cholera vaccines (BAU-FCV and LRI-FCV) in Jinding ducks. The ducks were divided into three groups (A = 14, B = 14, C = 12). Group A was inoculated with BAU- FCV 0.5 mL and group B with LRI- FCV 1.0 mL intramuscularly (im) at the age of six weeks and group C served as unvaccinated control. Booster vaccination was administered similarly at 11 weeks of age in groups A and B. Challenge infection was given to all birds two weeks after booster vaccination. Passive Haemagglutination Assay (PHA) antibody titres in group A were 59.4 ± 4.6 21 days after primary vaccination, 137.1 ± 21.8 15 days after booster vaccination, 100.6 ± 12.9 21 days after booster vaccination, and 256.0 ± 48.4 15 days after challenge. In group B, titres were 50.3 ± 6.5, 118.9 ± 9.1, 91.4 ± 12.9, 237.7 ± 51.7, respectively, whereas titres in group C remained at ?4.0 ± 0.0. The antibody titres were insignificant when compared between pre-vaccination and 21 days after primary vaccination in both vaccinated groups (A and B). PHA antibody titres of groups A were significantly (P < 0.0001) increased at 15 days after booster and in case of group B the antibody titres were insignificant. At 15 days after challenge the antibody titres were highly significant in both groups (A and B). There was no significant difference between the two vaccinated groups. Following challenge infection with virulent Pasteurella multocida 88.9% of birds vaccinated with BAU-FCV, and 77.8% of birds vaccinated with LRI-FCV survived, while all unvaccinated birds died. Both vaccines were safe and effective. DOI: http://dx.doi.org/10.3329/bvet.v30i2.18253 Bangl. vet. 2013. Vol. 30, No. 2, 41-45

scholarly journals Immune response of fowl cholera vaccine produced at Bangladesh Agricultural University in farm level

2015 ◽  
Vol 2 (1) ◽  
pp. 103-107
Author(s):  
Md Abdus Sattar Bag ◽  
Md Mansurul Amin ◽  
Md Bahanur Rahman ◽  
Yasir Ahammad Arafat ◽  
Md Salim ◽  
...  
Keyword(s):  
Booster Vaccination ◽  
Primary Vaccination ◽  
Control Group ◽  
Cholera Vaccine ◽  
Vaccine Research ◽  
Farm Level ◽  
Fowl Cholera ◽  
Unvaccinated Control ◽  
The Mean ◽  
Poultry Vaccine

The work was carried out to determine the immunogenicity of fowl cholera vaccine (FCV) produced by Livestock and Poultry Vaccine Research and Production Centre (LPVRPC) at Bangladesh Agricultural University (BAU). A total five hundred of sevenweek old Hy-sex chickens (both white and brown) were vaccinated @ 0.5 ml of 2.93×108 CFU through subcutaneous route in each selected groups such as A1, A2 and A3; and B1, B2 and B3. Booster dose was provided at 13 weeks of age in group A3 and B3. Group C was kept as unvaccinated/control. Postvaccination sera were collected at different time schedule from all the groups of birds and antibody against fowl cholera were determined by Passive haemagglutination (PHA) test. At 4 weeks of primary vaccination (11 weeks aged birds) the mean PHA titres of sera were 96.00±34.21 and 96.00±34.21in group A1 and B1 respectively. On the other hand mean PHA titres at 5-weeks following vaccination (12 weeks aged birds) were 88.00±33.12 and 96.00±34.21in group A2 and B2, respectively. After 4 weeks of booster vaccination the mean PHA titres were 104.00±33.12in A3 and 104.00±33.12 in B3 group. The mean PHA titres in chickens of unvaccinated control group C was <4±0.00.Fowl cholera vaccine prepared at LPVRPC induced a good level of immunity at the farm level and it was also demonstrated that booster (secondary) vaccination is essential to develop protective level of immunity.Res. Agric., Livest. Fish.2(1): 103-107, April 2015

scholarly journals Recombinant Modified Vaccinia Virus Ankara (MVA) Vaccines Efficiently Protect Cockatiels Against Parrot Bornavirus Infection and Proventricular Dilatation Disease

Viruses ◽  
2019 ◽  
Vol 11 (12) ◽  
pp. 1130 ◽  
Author(s):  
Isabell Rall ◽  
Ralf Amann ◽  
Sara Malberg ◽  
Christiane Herden ◽  
Dennis Rubbenstroth
Keyword(s):  
Vaccinia Virus ◽  
Challenge Infection ◽  
Control Group ◽  
Viral Loads ◽  
Breeding Populations ◽  
Modified Vaccinia Virus Ankara ◽  
Associated Lesions ◽  
Unvaccinated Control ◽  
Causative Agents ◽  
Proventricular Dilatation Disease

Parrot bornaviruses (PaBVs) are the causative agents of proventricular dilatation disease (PDD), a chronic and often fatal neurologic disorder in Psittaciformes. The disease is widely distributed in private parrot collections and threatens breeding populations of endangered species. Thus, immunoprophylaxis strategies are urgently needed. In previous studies we demonstrated a prime-boost vaccination regime using modified vaccinia virus Ankara (MVA) and Newcastle disease virus (NDV) constructs expressing the nucleoprotein and phosphoprotein of PaBV-4 (MVA/PaBV-4 and NDV/PaBV-4, respectively) to protect cockatiels (Nymphicus hollandicus) against experimental challenge infection. Here we investigated the protective effect provided by repeated immunization with either MVA/PaBV-4, NDV/PaBV-4 or Orf virus constructs (ORFV/PaBV-4) individually. While MVA/PaBV-4-vaccinated cockatiels were completely protected against subsequent PaBV-2 challenge infection and PDD-associated lesions, the course of the challenge infection in NDV/PaBV-4- or ORFV/PaBV-4-vaccinated birds did not differ from the unvaccinated control group. We further investigated the effect of vaccination on persistently PaBV-4-infected cockatiels. Remarkably, subsequent immunization with MVA/PaBV-4 and NDV/PaBV-4 neither induced obvious immunopathogenesis exacerbating the disease nor reduced viral loads in the infected birds. In summary, we demonstrated that vaccination with MVA/PaBV-4 alone is sufficient to efficiently prevent PaBV-2 challenge infection in cockatiels, providing a suitable vaccine candidate against avian bornavirus infection and bornavirus-induced PDD.

scholarly journals EVALUATION OF MATERNALLY DERIVED ANTIBODIES AGAINST NEWCASTLE DISEASE VIRUS AND ITS EFFECT ON VACCINATION IN BROILER CHICKS

2010 ◽  
Vol 7 (2) ◽  
pp. 296-302 ◽  
Author(s):  
MA Jalil ◽  
MA Samad ◽  
MT Islam
Keyword(s):  
Immune Response ◽  
Newcastle Disease ◽  
Humoral Immune Response ◽  
Broiler Chickens ◽  
Primary Vaccination ◽  
Challenge Infection ◽  
Broiler Chicks ◽  
Humoral Immune ◽  
Different Ages ◽  
Group B

The study was conducted to determine the persistence of maternally derived antibody (MDA) and its effects on protection against NDV in broiler chickens and to investigate the status of humoral immune response following vaccination with BCRDV® (F-strain, lentogenic) at different ages of broiler chickens during the period from August to October,  2008. A total of 90 day-old broiler chicks of Cobb 500 strain with the history of vaccination of parent stock against Newcastle disease (ND) was divided into three groups (A, B and C). Birds of group A (n = 35) were used for the study of protection ability of MDA against NDV, the birds of group B (n = 45) were used for the measurement of humoral immune response in chickens following vaccination at different ages and birds of group C (n = 10) were used for the determination of persistence of maternally derived antibody. The level of antibody titre against NDV was determined by HI test. The protective potentiality of MDA and vaccine was determined by the rate of survivability of the chickens following challenge infection. It was observed that the MDA titre in day-old chicks was higher and gradually declined at minimal level at day 28. The MDA titre of 128 or above protected the birds following challenge infection with virulent NDV. There were significant decrease in HI titres of chickens which were vaccinated once at day 1 and day 7, and could not withstand challenge infection with virulent NDV. Single vaccination with BCRDV® at day 14 triggered the production of antibody but could not provide complete protection to the birds. The birds which were boosted with the same vaccine 7 days and 21 days after primary vaccination produced better immune response. However, the birds which were vaccinated primarily at day 1 and boosted at day 7 could not withstand the challenge completely. Of the other regimens of twice vaccination, primary vaccination at day 7 and booster dosing at day 28 was found to be the best in terms of immune response and protection potentiality. Therefore, it may be concluded that (a) The MDA titre level of 128 or above is sufficient to protect broilers against challenge with virulent NDV,( b) Primary vaccination at day 7 followed by a booster dosing at day 28 may be followed for better immune response and protection against ND in broilers.DOI: 10.3329/bjvm.v7i2.5995Bangl. J. Vet. Med. (2009). 7(2) : 296 – 302

scholarly journals Efficacy of Feed-Based Formalin-Killed Vaccine of Streptococcus iniae Stimulates the Gut-Associated Lymphoid Tissues and Immune Response of Red Hybrid Tilapia

Vaccines ◽  
2021 ◽  
Vol 9 (1) ◽  
pp. 51
Author(s):  
Mohammad Hayat ◽  
Md Sabri Mohd Yusoff ◽  
Mohd Jamil Samad ◽  
Intan Shameha Abdul Razak ◽  
Ina Salwany Md Yasin ◽  
...  
Keyword(s):  
Immune Response ◽  
Booster Vaccination ◽  
Control Group ◽  
Lymphoid Tissues ◽  
Streptococcus Iniae ◽  
Specific Antibody Response ◽  
Post Vaccination ◽  
Oral Streptococcus ◽  
To Receive ◽  
Gut Lavage

Red hybrid tilapia were fed a formalin-killed oral Streptococcus iniae vaccine (FKV) in the present study was assessed. Three hundred Red hybrid tilapia 80 ± 10 g were divided into five groups (1A, 1B, 2A, 2B, and Cx), each consisting of 60 fish. Fish from Groups 1A, 1B, 2A, and 2B were fed with FKV over different periods of administration, while Group 2B was the only group of fish to receive an oral booster vaccination on day 14- and 21-days post-vaccination (dpv). Group Cx was fed with normal pellets containing no vaccine as a control group. At four weeks post-vaccination (wpv), all fish were experimentally infected with S. iniae. Groups 2A and 2B had the lowest level of mortalities following vaccination (45% and 30%, respectively) compared to Groups 1A and 1B (80% and 55%, respectively), while the level of mortalities in Group Cx was 100%. All vaccinated groups showed a significant increase in anti-S. iniae IgM levels (p < 0.05) in serum, mucus, and gut-lavage, while Group Cx did not (p > 0.05) and all fish in this group died by five weeks post-infection. In conclusion, fish fed with the S. iniae FKV had a greater level of protection against S. iniae, with increased specific antibody response to the vaccine and there was also evidence of GALT stimulation by the vaccine.

scholarly journals Efficacy study of bio-typhoid® vaccine against fowl typhoid in backyard layer chicken

1970 ◽  
Vol 7 (2) ◽  
pp. 295-299
Author(s):  
MZ Uddin ◽  
MSR Khan ◽  
F Begum ◽  
MA Mannan
Keyword(s):  
Antibody Titre ◽  
Virulent Strain ◽  
Primary Vaccination ◽  
Control Group ◽  
Fowl Typhoid ◽  
Layer Chicken ◽  
Unvaccinated Control ◽  
Antibody Titres ◽  
Group A ◽  
Group B

The study was performed with a view to isolate and identify a virulent strain of S. gallinarum and determine the purity, safety and efficacy of BIO-TYPHOID® vaccine. A total of 40 backyard layer chicken were used for this study where Group A was used for experimental vaccination, Group B kept as control and Group C was used for calculating virulent S. gallinarum challenge dose. Primary and secondary vaccination was carried out at 40 days and 110 days of age, respectively. Blood samples were collected to obtain the sera after vaccination from both vaccinated and unvaccinated control group and antibody titres were determined by Microplate agglutination test. The antibody titre increased in primary vaccination up to days 56 days post vaccination (DPV) and then decreased gradually. The highest antibody titre (Mean ± SE) 384.00 ± 42.67 was obtained at 91 DPV (21 days later of secondary vaccination) and maintained up to 98 DPV. Safety test was done by inoculating mice and purity test of the vaccine was done by inoculating on to Blood Agar media. The efficacy of BIO-TYPHOID® vaccine was recorded as 90% which was determined by challenge infection with 0.1 ml of 5x105 CFU virulent S. gallinarum. Results of this study revealed successful protections by BIO-TYPHOID® vaccine. Keywords: BIO-TYPHOID® vaccine; Chicken; Efficacy; Fowl Typhoid DOI: 10.3329/jbau.v7i2.4737 J. Bangladesh Agril. Univ. 7(2): 295-299, 2009

scholarly journals Determination of immune response of imported Newcastle disease virus vaccines in broiler chickens

1970 ◽  
Vol 6 (2) ◽  
pp. 139-144
Author(s):  
MS Islam ◽  
AKM Khasruzzaman ◽  
MT Hossain ◽  
MT Islam ◽  
MH Chowdhury ◽  
...  
Keyword(s):  
Immune Response ◽  
Newcastle Disease ◽  
Broiler Chickens ◽  
Geometric Mean ◽  
Primary Vaccination ◽  
Unvaccinated Control ◽  
Antibody Titres ◽  
Newcastle Disease Vaccine ◽  
Group 1

A study was undertaken to determine the immune response of eight different imported live NDV vaccines in broiler chickens in the Department of Microbiology and Hygiene, Bangladesh Agricultural University, Mymensingh during the period from July to December 2008. A total of 55 broiler chickens (Ross breed) were divided into eleven groups such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 and 11 of which group 1, 3, 5, 7 and 9 were vaccinated primarily with Nobilis® MA5+Clone30, Avipro® ND-IB HB1, Cevac® BIL, Newcastle-Bronchitis Vaccine Fortdodge® and Avipro® ND LaSota vaccine respectively at day 5 of age and secondarily with Nobilis® ND Clone 30, Avipro® ND LaSota, Cevac® New L, Newcastle Disease vaccine Fortdodge® and Avipro® ND LaSota vaccine respectively at day 21 of age by single eye instillation and 2, 4, 6, 8 and 10 were vaccinated with the same vaccines respectively by double eye instillation following the same schedule. Group 11 was kept as unvaccinated control. Sera samples were collected after 10 days of each vaccination and at day 5, 15, 20, 31 of age from nonvaccinated control and subjected to HI test for the determination of antibody titres. It was observed that after primary vaccination the geometric mean (GM) of HI titres of double eye vaccinated groups differed significantly (P

Sign in / Sign up

Export Citation Format

Share Document